ArticleFrontiers in oncology2012
Radiation-induced effects and the immune system in cancer.
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center Phase I Study of Sintilimab in Combination With Radiotherapy in Treatment Naive PD-L1 Positive Stage IV Non-small Cell Lung Cancer (NSCLC)
Safety and Preliminary Efficacy Study of NAD+Supplements (NMN) Combined With Radioimmunotherapy in Advanced Non Small Cell Lung Cancer Patients
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it, 229 citations in OpenAlex.
- A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger?PloS one · 2017Pooled it
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.European urology · 2020Trial
- Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.Journal for immunotherapy of cancer · 2019Trial
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.The Lancet. Oncology · 2014Trial
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Association of systemic immune-inflammation index with all-cause mortality in lung cancer patients undergoing radiotherapy: a retrospective cohort study.Frontiers in oncology · 2026Article
- CD8-positive lymphocyte infiltration as a marker of anti-tumor immune response in rectal cancer: pre- and post-neoadjuvant radiotherapy comparison.Clinical and translational radiation oncology · 2025Article
- Targeted Radiotherapy in Primary Cutaneous Lymphomas: Precision, Efficacy, and Evolving Strategies.Cancers · 2025Review
- Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.Current treatment options in oncology · 2025Review
- Multifunctional Hydrogels for Advanced Cancer Treatment: Diagnostic Imaging and Therapeutic Modalities.Gels (Basel, Switzerland) · 2025Review
- Review
- Understanding the early molecular changes associated with radiation therapy-A preliminary bulk RNA sequencing study.PloS one · 2025Article
- Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics.Frontiers in microbiology · 2025Review
- Potential immunogenic modulation of hypo-fractionated radiotherapy at optimal schedules and the subsequent vaccine-like effect of local irradiation - a systematic review.Frontiers in oncology · 2025Review
- Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor.Frontiers in immunology · 2025Review
- Pegylated Interferon Combined With Low-Dose Total Skin Electron Beam Therapy for Advanced Stage Mycosis Fungoides: Two Case Reports and Literature Review.Advances in radiation oncology · 2025Article
- Uveal melanoma distant metastasis prediction system: A retrospective observational study based on machine learning.Cancer science · 2024Observational
- Review
- Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours.Journal of clinical medicine · 2024Review
- Increased Risk of Breakthrough SARS-CoV-2 Infections in Patients with Colorectal Cancer: A Population-Based Propensity-Matched Analysis.Journal of clinical medicine · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy and radiation therapy (RT) are standard therapeutic modalities for patients with cancers, and could induce various tumor cell death modalities, releasing tumor-derived antigens as well as danger signals that could either be captured for triggering anti-tumor immune response. Historic studies examining tissue and cellular responses to RT have predominantly focused on damage caused to proliferating malignant cells leading to their death. However, there is increasing evidence that RT also leads to significant alterations in the tumor microenvironment, particularly with respect to effects on immune cells and infiltrating tumors. This review will focus on immunologic consequences of RT and discuss the therapeutic reprogramming of immune responses in tumors and how it regulates efficacy and durability to RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.